Summary: The combination of pamapimod and pioglitazone (KIN001) has a synergetic antiviral. anti-inflammatory. and antifibrotic activity. which may prevent evolution toward COVID-19-associated severe respiratory failure. https://www.socialstudiesscholar.com/